FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367836994> ?p ?o ?g. }

• W4367836994 abstract "Suitable selection criteria for focal therapy (FT) are crucial to achieve success in localized prostate cancer (PCa).To develop a multivariable model that better delineates eligibility for FT and reduces undertreatment by predicting unfavorable disease at radical prostatectomy (RP).Data were retrospectively collected from a prospective European multicenter cohort of 767 patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies followed by RP in eight referral centers between 2016 and 2021. The Imperial College of London eligibility criteria for FT were applied: (1) unifocal MRI lesion with Prostate Imaging-Reporting and Data System score of 3-5; (2) prostate-specific antigen (PSA) ≤20 ng/ml; (3) cT2-3a stage on MRI; and (4) International Society of Urological Pathology grade group (GG) 1 and ≥6 mm or GG 2-3. A total of 334 patients were included in the final analysis.The primary outcome was unfavorable disease at RP, defined as GG ≥4, and/or lymph node invasion, and/or seminal vesicle invasion, and/or contralateral clinically significant PCa. Logistic regression was used to assess predictors of unfavorable disease. The performance of the models including clinical, MRI, and biopsy information was evaluated using the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. A coefficient-based nomogram was developed and internally validated.Overall, 43 patients (13%) had unfavorable disease on RP pathology. The model including PSA, clinical stage on digital rectal examination, and maximum lesion diameter on MRI had an AUC of 73% on internal validation and formed the basis of the nomogram. Addition of other MRI or biopsy information did not significantly improve the model performance. Using a cutoff of 25%, the proportion of patients eligible for FT was 89% at the cost of missing 30 patients (10%) with unfavorable disease. External validation is required before the nomogram can be used in clinical practice.We report the first nomogram that improves selection criteria for FT and limits the risk of undertreatment.We conducted a study to develop a better way of selecting patients for focal therapy for localized prostate cancer. A novel predictive tool was developed using the prostate-specific antigen (PSA) level measured before biopsy, tumor stage assessed via digital rectal examination, and lesion size on magnetic resonance imaging (MRI) scans. This tool improves the prediction of unfavorable disease and may reduce the risk of undertreatment of localized prostate cancer when using focal therapy." @default.
• W4367836994 created "2023-05-04" @default.
• W4367836994 creator A5001474630 @default.
• W4367836994 creator A5012512780 @default.
• W4367836994 creator A5024472814 @default.
• W4367836994 creator A5026815613 @default.
• W4367836994 creator A5027982787 @default.
• W4367836994 creator A5041338029 @default.
• W4367836994 creator A5044981833 @default.
• W4367836994 creator A5045293970 @default.
• W4367836994 creator A5052350556 @default.
• W4367836994 creator A5057962494 @default.
• W4367836994 creator A5058270075 @default.
• W4367836994 creator A5064133295 @default.
• W4367836994 creator A5066738891 @default.
• W4367836994 creator A5074146875 @default.
• W4367836994 creator A5079922637 @default.
• W4367836994 creator A5080577974 @default.
• W4367836994 creator A5088072625 @default.
• W4367836994 creator A5089418625 @default.
• W4367836994 creator A5089740337 @default.
• W4367836994 date "2023-05-01" @default.
• W4367836994 modified "2023-10-18" @default.
• W4367836994 title "A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging–Targeted and Systematic Biopsies: A European Multicenter Study" @default.
• W4367836994 cites W1549611683 @default.
• W4367836994 cites W1983394054 @default.
• W4367836994 cites W2045030989 @default.
• W4367836994 cites W2078271269 @default.
• W4367836994 cites W2546110733 @default.
• W4367836994 cites W2601227959 @default.
• W4367836994 cites W2770547479 @default.
• W4367836994 cites W2778234364 @default.
• W4367836994 cites W2799837109 @default.
• W4367836994 cites W2803596246 @default.
• W4367836994 cites W2896430583 @default.
• W4367836994 cites W2913870380 @default.
• W4367836994 cites W2923307878 @default.
• W4367836994 cites W2972245785 @default.
• W4367836994 cites W2973334574 @default.
• W4367836994 cites W3023898905 @default.
• W4367836994 cites W3027874948 @default.
• W4367836994 cites W3091748082 @default.
• W4367836994 cites W3091931232 @default.
• W4367836994 cites W3097158220 @default.
• W4367836994 cites W3119966384 @default.
• W4367836994 cites W3185119287 @default.
• W4367836994 cites W3201361969 @default.
• W4367836994 cites W4210442651 @default.
• W4367836994 cites W4213258135 @default.
• W4367836994 cites W4282931683 @default.
• W4367836994 cites W4296621715 @default.
• W4367836994 cites W4298003754 @default.
• W4367836994 cites W4298858023 @default.
• W4367836994 cites W4308347512 @default.
• W4367836994 cites W4308419397 @default.
• W4367836994 cites W4311605616 @default.
• W4367836994 cites W4313576817 @default.
• W4367836994 cites W4315754639 @default.
• W4367836994 doi "https://doi.org/10.1016/j.euf.2023.04.008" @default.
• W4367836994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37147167" @default.
• W4367836994 hasPublicationYear "2023" @default.
• W4367836994 type Work @default.
• W4367836994 citedByCount "3" @default.
• W4367836994 countsByYear W43678369942023 @default.
• W4367836994 crossrefType "journal-article" @default.
• W4367836994 hasAuthorship W4367836994A5001474630 @default.
• W4367836994 hasAuthorship W4367836994A5012512780 @default.
• W4367836994 hasAuthorship W4367836994A5024472814 @default.
• W4367836994 hasAuthorship W4367836994A5026815613 @default.
• W4367836994 hasAuthorship W4367836994A5027982787 @default.
• W4367836994 hasAuthorship W4367836994A5041338029 @default.
• W4367836994 hasAuthorship W4367836994A5044981833 @default.
• W4367836994 hasAuthorship W4367836994A5045293970 @default.
• W4367836994 hasAuthorship W4367836994A5052350556 @default.
• W4367836994 hasAuthorship W4367836994A5057962494 @default.
• W4367836994 hasAuthorship W4367836994A5058270075 @default.
• W4367836994 hasAuthorship W4367836994A5064133295 @default.
• W4367836994 hasAuthorship W4367836994A5066738891 @default.
• W4367836994 hasAuthorship W4367836994A5074146875 @default.
• W4367836994 hasAuthorship W4367836994A5079922637 @default.
• W4367836994 hasAuthorship W4367836994A5080577974 @default.
• W4367836994 hasAuthorship W4367836994A5088072625 @default.
• W4367836994 hasAuthorship W4367836994A5089418625 @default.
• W4367836994 hasAuthorship W4367836994A5089740337 @default.
• W4367836994 hasConcept C121608353 @default.
• W4367836994 hasConcept C126322002 @default.
• W4367836994 hasConcept C126838900 @default.
• W4367836994 hasConcept C143409427 @default.
• W4367836994 hasConcept C143998085 @default.
• W4367836994 hasConcept C146357865 @default.
• W4367836994 hasConcept C151730666 @default.
• W4367836994 hasConcept C2775934546 @default.
• W4367836994 hasConcept C2776235491 @default.
• W4367836994 hasConcept C2778162587 @default.
• W4367836994 hasConcept C2779466945 @default.
• W4367836994 hasConcept C2780192828 @default.
• W4367836994 hasConcept C2780849966 @default.
• W4367836994 hasConcept C2781406297 @default.
• W4367836994 hasConcept C34626388 @default.
• W4367836994 hasConcept C58471807 @default.

• next